世界の心血管・脳血管疾患市場（2023年版）：薬剤タイプ別、適応症別、地域別、国別の分析：推進要因、動向、2029年までの予測

Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country: Drivers, Trends and Forecast to 2029

エグゼクティブ・サマリー Azoth Analytics社はこのたび、「心血管・脳血管市場（2023年版）」と題する調査レポートを発表しました、薬剤タイプ別（抗血小板剤、抗凝固剤、降圧剤、スタチン、その他の薬剤）、... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年8月1日	US$2,450 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	230	英語

サマリー

エグゼクティブ・サマリー

Azoth Analytics社はこのたび、「心血管・脳血管市場（2023年版）」と題する調査レポートを発表しました、薬剤タイプ別（抗血小板剤、抗凝固剤、降圧剤、スタチン、その他の薬剤）、適応症別（高血圧、心房細動、脳卒中、脳動脈瘤、心筋梗塞、その他の適応症）に、過去期間の2019-2022年、推定期間の2023年、予測期間の2024-2029年について分析しています。

調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、英国、ドイツ、フランス、イタリア、スペイン、中国、インド、日本）の詳細な分析をカバーしている。さらに、市場規模、年間成長＆潜在力分析、市場プレイヤーの競合調査、投資機会、需要予測などのデータも掲載しています。

予測期間2024-2029年、世界の心血管・脳血管市場はCAGR 8.12%で成長すると予測される。

世界の心血管・脳血管市場は、2022年の698億5,000万米ドルから2029年末までに1,300億米ドルを創出すると予測される。CVD市場の規模は大きく、成長を続けているが、市場の主要医薬品の特許切れとジェネリック医薬品の台頭により、成長ペースは鈍化している。

心血管疾患と脳血管疾患は世界の主要な死因である。世界保健機関（WHO）の報告によると、2019年の心血管疾患関連の死亡者数は推定1,790万人で、全世界の死亡者数の32％を占めている。脳卒中と虚血性心疾患の2つが、この負担の最も大きな原因となっている。これらの疾患の有病率は地域によって異なり、人口統計学的要因、ライフスタイルの変化、医療へのアクセスに影響される。

加齢は心血管疾患や脳血管疾患を発症する可能性を高める。高齢になると血管の柔軟性が低下し、傷害を受けやすくなる。

レポートの範囲

- このレポートは心臓血管および脳血管市場を金額（億米ドル）別に分析しています。

- 本レポートでは、心血管・脳血管市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介します。

- 当レポートでは、心血管・脳血管市場を薬剤タイプ別（抗血小板薬、抗凝固薬、降圧薬、スタチン、その他の薬剤）に分析しています。

- 心血管・脳血管市場を適応症別（高血圧、心房細動、脳卒中、脳動脈瘤、心筋梗塞、その他の適応症）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、サービス別、操作モード別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 競合の動向、戦略、M&A、新製品開発についても追跡しています。本レポートで分析対象とした企業は、ベーリンガーインゲルハイム、ノボノルディスク、サノフィ、アストラゼネカPLC、メルク社、ジョンソン・エンド・ジョンソン、ファイザー、アボット・ラボラトリーズ、ブリストル・マイヤーズスクイブ社、バイエルなどです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

2.1 Utilisation of Artificial intelligence in Diagnostics and therapeutics development

2.2 Increasing investments in R&D operations for the development of novel treatments

3. Global Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

3.1 Impact Analysis of Macro Economic Factors on the Cardiovascular and Cerebrovascular Diseases Market

3.2 Prevalence of Cardiovascular Diseases (2019)

3.3 Cardiovascular Diseases Top marketed drugs and Top Pipeline drugs

3.4 Competitive landscape for CVD drugs in Pipeline

3.5 Global Cardiovascular and Cerebrovascular Diseases Market: Dashboard

3.6 Global Cardiovascular and Cerebrovascular Diseases Market: Market Value Assessment, 2019-2029 (USD Billion)

3.7 Impact of COVID-19 on Global Cardiovascular and Cerebrovascular Diseases Market

3.8 Global Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type

3.8.1 Global Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Type Overview

3.8.2 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.3 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.4 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.5 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.6 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)

3.9 Global Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication

3.9.1 Global Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview

3.9.2 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.3 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.4 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.5 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.6 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.7 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

4. Global Cardiovascular and Cerebrovascular Diseases Market, Regional Analysis

5. Americas Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

5.1 Americas Cardiovascular and Cerebrovascular Diseases Market: Snapshot

5.2 Americas Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.3 Americas Cardiovascular and Cerebrovascular Diseases Market: Key Factors

5.4 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type

5.4.1 Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview

5.4.2 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)

5.4.3 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)

5.4.4 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)

5.4.5 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)

5.4.6 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)

5.5 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication

5.5.1 Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview

5.5.2 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.3 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.4 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.5 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.6 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.7 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

5.6 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country

5.6.1 United States Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.6.1.1 United States Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

5.6.1.2 United States Cardiovascular and Cerebrovascular Diseases Market, By Indication

5.6.2 Canada Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.6.2.1 Canada Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

5.6.2.2 Canada Cardiovascular and Cerebrovascular Diseases Market, By Indication

5.6.3 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.6.3.1 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

5.6.3.2 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication

6. Europe Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

6.1 Europe Cardiovascular and Cerebrovascular Diseases Market: Snapshot

6.2 Europe Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.3 Europe Cardiovascular and Cerebrovascular Diseases Market: Key Factors

6.4 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type

6.4.1 Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview

6.4.2 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)

6.4.3 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)

6.4.4 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)

6.4.5 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)

6.4.6 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)

6.5 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication

6.5.1 Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview

6.5.2 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.3 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.4 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.5 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.6 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.7 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

6.6 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country

6.6.1 France Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.1.1 France Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.1.2 France Cardiovascular and Cerebrovascular Diseases Market, By Indication

6.6.2 United Kingdom Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.2.1 United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.2.2 United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Indication

6.6.3 Italy Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.3.1 Italy Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.3.2 Italy Cardiovascular and Cerebrovascular Diseases Market, By Indication

6.6.4 Spain Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.4.1 Spain Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.4.2 Spain Cardiovascular and Cerebrovascular Diseases Market, By Indication

6.6.5 Germany Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.5.1 Germany Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.5.2 Germany Cardiovascular and Cerebrovascular Diseases Market, By Indication

6.6.6 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.6.6.1 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

6.6.6.2 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication

7. Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

7.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Snapshot

7.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Key Factors

7.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type

7.4.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview

7.4.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)

7.4.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)

7.4.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)

7.4.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)

7.4.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)

7.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication

7.5.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview

7.5.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.7 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

7.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country

7.6.1 China Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.6.1.1 China Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

7.6.1.2 China Cardiovascular and Cerebrovascular Diseases Market, By Indication

7.6.2 Japan Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.6.2.1 Japan Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

7.6.2.2 Japan Cardiovascular and Cerebrovascular Diseases Market, By Indication

7.6.3 India Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.6.3.1 India Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

7.6.3.2 India Cardiovascular and Cerebrovascular Diseases Market, By Indication

7.6.4. Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.6.4.1 Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type

7.6.4.2 Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication

8. Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

8.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Snapshot

8.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

8.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Key Factors

8.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type

8.4.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview

8.4.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)

8.4.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)

8.4.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)

8.4.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)

8.4.6 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)

8.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication

8.5.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview

8.5.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.6 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.7 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Cardiovascular and Cerebrovascular Diseases Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Macro-Economic Factor Assessment

10.2 Porter’s Five Forces Model

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of Cardiovascular and Cerebrovascular Diseases Market

11.4 Company Profiles

11.4.1 Boehringer Ingelheim

11.4.2 Novo Nordisk

11.4.3 Sanofi

11.4 .4 AstraZeneca PLC

11.4.5 Merck & Co., Inc.

11.4.6 Johnson & Johnson

11.4.7 Pfizer

11.4.8 Abbott Laboratories

11.4.9 Bristol-Myers Squibb Co.

11.4.10 Bayer

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Cardiovascular and Cerebrovascular Market (2023 Edition)” which provides a complete analysis of the global Cardiovascular and Cerebrovascular industry by Drug Type (Antiplatelet Agents, Anticoagulants, Antihypertensive Agents, Statins, Other Drugs) and By Indication (Hypertension, Atrial Fibrillation, Stroke, Cerebral Aneurysms, Myocardial Infraction, Other Indications) for the historical period of 2019-2022, estimated figures of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, India, Japan). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

During the forecast period, 2024-2029, the Global Cardiovascular and Cerebrovascular market is expected to grow at a CAGR of 8.12%.

The Global Cardiovascular and Cerebrovascular Market is expected to generate ~USD 130 Billion by the end of 2029, up from USD 69.85 Billion in 2022. The CVD market is significant in size and continues to grow, however, at a slower pace owing to patent expirations of major drugs in the market and the rise of generics.

Cardiovascular and cerebrovascular diseases are the world's primary causes of death. As reported by the World Health Organization (WHO), there were an estimated 17,9 million cardiovascular disease-related fatalities in 2019, accounting for 32 per cent of all global deaths. Stroke and ischemic heart disease were the two most significant contributors to this burden. The prevalence of these diseases differs by region and is influenced by demographic factors, lifestyle changes, and healthcare accessibility.

Age increases the likelihood of developing cardiovascular and cerebrovascular diseases. As people age, their blood vessels become less flexible and more prone to injury, which is a major driver of the CVD industry.

Scope of the Report:

• The report analyses the Cardiovascular and Cerebrovascular Market by Value (USD Billion).

• The report presents the analysis of the Cardiovascular and Cerebrovascular Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Cardiovascular and Cerebrovascular Market by Drug Type (Antiplatelet Agents, Anticoagulants, Antihypertensive Agents, Statins, Other drugs).

• The report analyses the Cardiovascular and Cerebrovascular Market by Indication (Hypertension, Atrial Fibrillation, Stroke, Cerebral Aneurysms, Myocardial Infraction, Other Indications).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, Novo Nordisk, Sanofi, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson, Pfizer, Abbott Laboratories, Bristol-Myers Squibb Co., and Bayer.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（個々の器官作用薬）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（cardiovascular）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

世界の心血管・脳血管疾患市場（2023年版）：薬剤タイプ別、適応症別、地域別、国別の分析：推進要因、動向、2029年までの予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（個々の器官作用薬）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（cardiovascular）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?